Nationwide Fund Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Nationwide Fund Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,931	Closed	-$47K	–	3138
2017 Q3	$47K	Hold	13,931	–	–	﹤0.01%	3046
2017 Q2	$49K	Hold	13,931	–	–	﹤0.01%	3058
2017 Q1	$47K	Hold	13,931	–	–	﹤0.01%	2996
2016 Q4	$64K	Buy	13,931 +3,926	+39%	+$16.2K	﹤0.01%	2970
2016 Q3	$42K	Hold	10,005	–	–	﹤0.01%	3075
2016 Q2	$24K	Buy	10,005 +3,348	+50%	+$12.1K	﹤0.01%	3145
2016 Q1	$31K	Hold	6,657	–	–	﹤0.01%	3058
2015 Q4	$26K	Hold	6,657	–	–	﹤0.01%	3056
2015 Q3	$26K	Hold	6,657	–	–	﹤0.01%	3106
2015 Q2	$31K	Buy	+6,657	New	+$63.8K	﹤0.01%	3133

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nationwide Fund Advisors's AST Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2017, closing a stake of 13,931 shares — an estimated $47K sold.

Nationwide Fund Advisors first reported a position in AST in Q2 2015 and held it in 10 quarters. The position peaked at $64K in Q4 2016. 75 funds tracked by Wall St. Rank hold AST as of Q4 2017.

Nationwide Fund Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 13,931 Asterias Biotherapeutics Inc. Series A shares in Q4 2017, an estimated $47K.
Nationwide Fund Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 10 quarters.
Nationwide Fund Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $64K in Q4 2016.
75 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.